ADAM10 vs ADAM17 — Antibody Selection Guide

Choose ADAM10 antibodies when investigating constitutive α-secretase activity, Notch S2 cleavage, or non-amyloidogenic processing of amyloid precursor protein; choose ADAM17 when studying inducible TNF-alpha release, IL-6 receptor shedding, or EGFR ligand activation. Both are zinc metalloproteinases that cleave overlapping but distinct substrate panels, and the decision hinges on which signaling axis or disease mechanism you are interrogating.

ADAM10 and ADAM17 are frequently conflated because both belong to the ADAM family of membrane-anchored sheddases, both process Notch receptors and APP, and both release soluble ectodomains that activate or terminate downstream signaling. Yet their regulation, substrate preference, tissue distribution, and pathophysiological roles diverge in ways that matter experimentally. ADAM10 operates constitutively under tetraspanin control and serves as the dominant α-secretase in neurons, while ADAM17 is acutely activated by MAPK phosphorylation and inflammatory stimuli and was originally defined by its ability to convert membrane TNF-alpha to its soluble form. Selecting the correct antibody requires clarity about which protease mediates the biological event under study.

Quick Comparison Table

When to Choose ADAM10

Select ADAM10 antibodies when your experimental system centers on constitutive ectodomain shedding, Notch-dependent cell fate decisions, or the non-amyloidogenic pathway of amyloid precursor protein processing. ADAM10 is the principal α-secretase in the central nervous system, cleaving APP within the amyloid-beta sequence to preclude formation of neurotoxic peptides. Loss-of-function studies in mice confirm that ADAM10 is essential for embryonic development—global knockout is lethal by E9.5 due to defects in cardiovascular and somite formation driven by impaired Notch signaling. Conditional knockouts in T cells reveal requirements for CD23, CD44, and IL-6 receptor shedding during immune activation.

ADAM10 is trafficked to the plasma membrane by six TspanC8 tetraspanins (Tspan5, Tspan10, Tspan14, Tspan15, Tspan17, and Tspan33), which regulate both its ER exit and substrate access. If your model involves tetraspanin modulation—pharmacological, genetic, or through palmitoylation mutants—ADAM10 is the relevant sheddase. ADAM10 also processes ephrin-A2 during axon guidance, N-cadherin during synaptic remodeling, and the cellular prion protein (PrP^C) in prion disease models. In cancer biology, ADAM10-mediated shedding of L1CAM, HER2, and CD44 correlates with invasive phenotypes in breast, ovarian, and colorectal tumors.

Triple Point Biologics offers four rabbit polyclonal antibodies raised against the cytoplasmic domain of ADAM10 (residues approximately 698–748). Because this epitope is preserved across mammalian orthologs, predicted cross-reactivity extends to mouse, rat, dog, and non-human primate samples. The cytoplasmic tail is accessible for immunoprecipitation and detects both the mature 84 kDa form and the 98 kDa proenzyme on Western blots. Immunohistochemistry on paraffin-embedded human brain sections shows membrane and perinuclear staining consistent with plasma membrane and Golgi localization. These reagents are appropriate for mechanistic studies of α-secretase function, tetraspanin co-immunoprecipitation, and substrate validation experiments in cell lines or tissue lysates.

When to Choose ADAM17

Choose ADAM17 antibodies when investigating inducible shedding events, inflammatory signaling through TNF-alpha or IL-6 receptor, EGFR transactivation via ligand release, or pathogen interactions involving ACE2. ADAM17 was cloned in 1997 as the protease responsible for converting 26 kDa membrane-bound pro-TNF-alpha into the 17 kDa soluble cytokine, and remains the only known TNF convertase. Mice lacking ADAM17 die perinatally with open eyelids, malformed heart valves, and defects in epithelial development—phenotypes explained by impaired EGFR ligand shedding (TGF-alpha, amphiregulin, HB-EGF).

ADAM17 activity is regulated post-translationally by MAPK-dependent phosphorylation of its cytoplasmic tail, by iRhom1/iRhom2-mediated ER-to-Golgi trafficking, and by interactions with tissue inhibitors of metalloproteinases (TIMPs). Stimuli such as phorbol esters (PMA), LPS, and growth factors trigger rapid ADAM17-dependent shedding within minutes, making it the dominant sheddase in acute inflammatory responses. ADAM17 also cleaves the IL-6 receptor to generate soluble IL-6R, which mediates trans-signaling and drives STAT3 activation in tumor microenvironments and inflamed tissues. In cardiovascular disease, ADAM17 sheds L-selectin from leukocytes and processes ACE2, the SARS-CoV-2 receptor, influencing both viral entry and the renin-angiotensin system.

ADAM17 is expressed broadly, with highest levels in heart, placenta, pancreas, and immune cells. In oncology, elevated ADAM17 correlates with poor prognosis in breast, colon, and gastric cancers, where it liberates EGFR ligands that drive autocrine proliferation and resistance to EGFR inhibitors. ADAM17 inhibitors (including INCB7839 and INCB3619) have been evaluated clinically for rheumatoid arthritis and cancer, though selectivity remains a challenge due to overlapping substrate profiles with ADAM10.

Triple Point Biologics provides four rabbit polyclonal antibodies targeting the propeptide domain of ADAM17. The propeptide (residues approximately 18–215) is cleaved during maturation but may remain associated with the protease or be detectable in biosynthetic intermediates. On Western blots, expect detection of the 120 kDa proform in cell lysates and the 93 kDa mature form at the plasma membrane. The antibodies are validated for human samples and show predicted cross-reactivity with mouse, rat, and pig orthologs. These reagents suit experiments addressing ADAM17 expression in inflammatory disease models, inhibitor validation, or co-immunoprecipitation with iRhom scaffold proteins.

Can They Be Used Together?

Yes, and paired detection is often necessary to parse substrate specificity or compensatory mechanisms. While ADAM10 and ADAM17 share substrates—including Notch receptors, APP, and certain cytokines—their contributions differ by cell type, activation state, and subcellular localization. For example, constitutive Notch signaling in resting T cells depends on ADAM10, whereas PMA-induced Notch shedding recruits ADAM17. In neurons, ADAM10 dominates α-secretase activity under basal conditions, but ADAM17 may compensate when ADAM10 is silenced or inhibited.

Co-detection on Western blots is straightforward because the two proteases migrate at distinct molecular weights: ADAM10 mature form at ~84 kDa, ADAM17 mature form at ~93 kDa. Running paired samples—wild-type versus ADAM10 knockout, or vehicle versus PMA-stimulated—clarifies which protease mediates a given shedding event. Immunofluorescence co-staining can reveal differential subcellular localization: ADAM10 colocalizes with tetraspanin-enriched microdomains and recycling endosomes, while ADAM17 accumulates at the ER and Golgi in complex with iRhoms before stimulus-driven surface delivery.

In functional studies, pharmacological inhibitors offer limited selectivity—GI254023X preferentially inhibits ADAM10 (IC₅₀ ~5 nM) over ADAM17 (IC₅₀ ~541 nM), while TAPI-1 and marimastat inhibit both. Genetic approaches (siRNA, CRISPR knockout, or dominant-negative constructs) paired with TPB antibodies allow definitive assignment of substrate cleavage. Co-immunoprecipitation experiments can also distinguish interacting partners: ADAM10 pulls down TspanC8 tetraspanins, whereas ADAM17 associates with iRhom2 and TIMP3.

Cross-Reactivity Considerations

ADAM10 and ADAM17 share a common domain architecture—signal peptide, prodomain, metalloprotease domain, disintegrin-like region, cysteine-rich domain, EGF repeat, transmembrane helix, and cytoplasmic tail—but sequence identity is modest (~40% overall). The cytoplasmic tails, which serve as antibody epitopes for TPB ADAM10 reagents, are short (~50 residues) and poorly conserved between the two proteases, minimizing cross-reactivity risk. Similarly, the ADAM17 propeptide domain targeted by TPB antibodies is structurally and functionally distinct from the ADAM10 prodomain.

Within species, cross-reactivity is predicted based on epitope conservation. Human ADAM10 cytoplasmic domain shares >90% identity with mouse, rat, and dog orthologs, supporting the use of TPB ADAM10 antibodies across these species. Human ADAM17 propeptide is likewise well-conserved in mouse (>85% identity) and rat, with slightly lower homology to pig (~80%). Researchers working with non-mammalian models (zebrafish, Xenopus) should verify epitope alignment before assuming cross-reactivity; ADAM proteases exist in these organisms but with greater sequence divergence.

Because both antibodies are rabbit polyclonals, they recognize multiple epitopes within their target domains, increasing detection robustness but also raising the possibility of non-specific bands. Western blots should include knockout or knockdown controls to confirm band identity. Preabsorption with blocking peptide (if available) or comparison to isotype control in IHC further validates specificity.

TPB Antibody Specifications

Triple Point Biologics has supplied proteinase and inhibitor antibodies to academic and industry researchers since 1994. Both ADAM10 and ADAM17 antibody panels were developed in rabbits, affinity-purified, and validated on human tissue lysates and paraffin sections.

ADAM10 antibodies: Four rabbit polyclonal SKUs (RP1ADAM10, RP2ADAM10, RP3ADAM10, RP4ADAM10) raised against recombinant cytoplasmic domain (C-terminal ~50 residues). Validated for Western blot (detects 84 kDa mature and 98 kDa proform), immunohistochemistry (paraffin), and immunofluorescence. Predicted cross-reactivity: human, mouse, rat, dog, non-human primate. Supplied as affinity-purified IgG in PBS with 0.02% sodium azide. View ADAM10 antibody details and order.

ADAM17 antibodies: Four rabbit polyclonal SKUs targeting the propeptide domain (residues ~18–215). Validated for Western blot (93 kDa mature, 120 kDa proform), immunohistochemistry, and immunofluorescence. Predicted cross-reactivity: human, mouse, rat, pig. Supplied as affinity-purified IgG. View ADAM17 antibody details and order.

Both sets are suitable for lysate preparation from cultured cells (use RIPA buffer with protease inhibitor cocktail), tissue homogenates, and formalin-fixed paraffin-embedded sections following heat-mediated antigen retrieval. For immunoprecipitation, the ADAM10 cytoplasmic epitope is accessible in native conditions; ADAM17 propeptide IP may capture biosynthetic intermediates or cleaved prodomain fragments depending on cell type and lysis conditions.

References

1. Seegar TCM, Killingsworth LB, Saha N, Meyer PA, Patra D, Zimmerman B, et al. Structural basis for regulated proteolysis by the α-secretase ADAM10. Cell. 2017;171(7):1638–1648.e7.
2. Zunke F, Rose-John S. The shedding protease ADAM17: Physiology and pathophysiology. Biochim Biophys Acta Mol Cell Res. 2017;1864(11 Pt B):2059–2070.
3. Saftig P, Lichtenthaler SF. The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain. Prog Neurobiol. 2015;135:1–20.
4. Düsterhöft S, Lokau J, Garbers C. The metalloprotease ADAM17 in inflammation and cancer. Pathol Res Pract. 2019;215(6):152410.